$222.97 Million in Sales Expected for Masimo Co. (NASDAQ:MASI) This Quarter

Analysts expect that Masimo Co. (NASDAQ:MASI) will report $222.97 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Masimo’s earnings. The lowest sales estimate is $222.30 million and the highest is $223.52 million. Masimo posted sales of $211.62 million during the same quarter last year, which would indicate a positive year over year growth rate of 5.4%. The firm is scheduled to issue its next earnings results on Wednesday, August 7th.

On average, analysts expect that Masimo will report full-year sales of $919.37 million for the current fiscal year, with estimates ranging from $918.70 million to $920.20 million. For the next fiscal year, analysts expect that the firm will post sales of $1.01 billion, with estimates ranging from $1.00 billion to $1.02 billion. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Masimo.

Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Monday, May 6th. The medical equipment provider reported $0.79 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.75 by $0.04. Masimo had a return on equity of 18.61% and a net margin of 22.49%. The firm had revenue of $231.70 million during the quarter, compared to analyst estimates of $223.67 million. During the same period last year, the company posted $0.75 EPS. The business’s quarterly revenue was up 8.8% on a year-over-year basis.

A number of analysts have commented on the company. Stifel Nicolaus boosted their price objective on Masimo from $150.00 to $160.00 and gave the stock a “buy” rating in a report on Friday, May 17th. Zacks Investment Research downgraded Haynes International from a “hold” rating to a “sell” rating in a research note on Wednesday, May 8th. BTIG Research downgraded Masimo from a “buy” rating to a “neutral” rating and set a $134.50 target price on the stock. in a research note on Tuesday, April 16th. BidaskClub upgraded Winmark from a “sell” rating to a “hold” rating in a research note on Tuesday, May 14th. Finally, Piper Jaffray Companies boosted their target price on Adverum Biotechnologies from $8.00 to $12.00 and gave the stock an “overweight” rating in a research note on Friday, May 17th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Masimo presently has a consensus rating of “Buy” and an average price target of $154.25.

Shares of MASI stock traded up $1.40 during mid-day trading on Friday, hitting $154.18. The company’s stock had a trading volume of 162,288 shares, compared to its average volume of 431,307. The stock’s fifty day simple moving average is $144.26. Masimo has a 52 week low of $96.14 and a 52 week high of $155.13. The company has a market cap of $8.15 billion, a P/E ratio of 50.88, a PEG ratio of 3.04 and a beta of 1.14.

In other news, EVP Anand Sampath sold 30,000 shares of the company’s stock in a transaction on Friday, June 14th. The shares were sold at an average price of $142.39, for a total value of $4,271,700.00. Following the transaction, the executive vice president now owns 27,518 shares of the company’s stock, valued at $3,918,288.02. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Yongsam Lee sold 5,989 shares of the company’s stock in a transaction on Friday, July 12th. The stock was sold at an average price of $151.83, for a total transaction of $909,309.87. Following the completion of the transaction, the executive vice president now directly owns 78,339 shares in the company, valued at approximately $11,894,210.37. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 204,731 shares of company stock worth $30,167,113. Company insiders own 11.50% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. Commonwealth Equity Services LLC lifted its holdings in shares of Masimo by 2.6% during the 4th quarter. Commonwealth Equity Services LLC now owns 4,413 shares of the medical equipment provider’s stock valued at $473,000 after buying an additional 113 shares during the last quarter. Raymond James Financial Services Advisors Inc. lifted its holdings in shares of Masimo by 62.4% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 6,972 shares of the medical equipment provider’s stock valued at $749,000 after buying an additional 2,679 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of Masimo by 0.7% during the 4th quarter. Northern Trust Corp now owns 375,838 shares of the medical equipment provider’s stock valued at $40,354,000 after buying an additional 2,444 shares during the last quarter. Great West Life Assurance Co. Can lifted its holdings in shares of Masimo by 44.7% during the 4th quarter. Great West Life Assurance Co. Can now owns 39,030 shares of the medical equipment provider’s stock valued at $3,964,000 after buying an additional 12,064 shares during the last quarter. Finally, United Services Automobile Association lifted its holdings in shares of Masimo by 1.9% during the 4th quarter. United Services Automobile Association now owns 69,299 shares of the medical equipment provider’s stock valued at $7,441,000 after buying an additional 1,295 shares during the last quarter. 83.02% of the stock is currently owned by hedge funds and other institutional investors.

Masimo Company Profile

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Further Reading: What is an investor looking for in an SEC filing?

Get a free copy of the Zacks research report on Masimo (MASI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.